Showing 431-440 of 867 results for "".
- Alimera Sciences Appoints David Dyer, MD, as Chief Retina Specialisthttps://modernod.com/news/alimera-sciences-appoints-david-dyer-md-as-chief-retina-specialist/2479222/Alimera Sciences has announced the expansion of its leadership team with the appointment of David Dyer, MD, as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business exp
- EyePoint Pharmaceuticals Appoints David Guyer, MD, to Board of Directorshttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-guyer-md-to-board-of-directors/2479602/EyePoint Pharmaceuticals announced the appointment of David Guyer, MD, to the company’s Board of Directors. He will also serve on the company’s Science Committee. Dr. Guyer has led several public and private biotechnology companies focused on ocular diseases, and has held leadership positi
- Visus Therapeutics Appoints David Guyer, MD, as Chairman of the Board, and Names Ted Danse as Head of Business Developmenthttps://modernod.com/news/visus-therapeutics-appoints-david-guyer-md-as-chairman-of-the-board-and-names-ted-danse-as-head-of-business-development/2480395/Visus Therapeutics announced the appointment of ophthalmology and industry expert David Guyer, MD, as the chairman of the Board after serving as an advisor since the company’s inception, and life sciences veteran Ted Danse as the head of business development. “I&rs
- David R. Guyer, MD, to Step Down from Iveric Bio Board to Rejoin Venture Fundhttps://modernod.com/news/david-r-guyer-md-to-step-down-from-iveric-bio-board-to-rejoin-venture-fund/2479050/Iveric bio announced that David R. Guyer, MD, co-founder and Executive Chairman, is stepping down from the Iveric Bio Board after 14 years, effective following Iveric Bio’s 2021 Annual Stockholder Meeting scheduled to be held on May 19, 2021. Dr. Guyer has served as the Chairman of Iveric’
- Aerie Pharmaceuticals Announces the Appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officerhttps://modernod.com/news/aerie-pharmaceuticals-announces-the-appointment-of-david-a-hollander-md-mba-as-chief-research-development-officer/2477056/Aerie Pharmaceuticals announced the appointment of David A. Hollander, MD, MBA, as Chief Research & Development Officer, an executive officer position reporting to Vicente Anido, Jr., PhD, Aerie’s Chairman and Chief Executive Officer. Dr. Hollander will commence his employment at Aerie on Nov
- David Rostov Joins CorneaGen as Chief Financial Officerhttps://modernod.com/news/david-rostov-joins-corneagen-as-chief-financial-officer/2477648/CorneaGen announced that David Rostov has joined the company as chief financial officer. Mr. Rostov has more than 20 years of C-suite experience in scaling fast-growing technology companies, mergers and acquisitions and corpor
- BVI Names David Murray as Chief Financial Officerhttps://modernod.com/news/bvi-names-david-murray-as-chief-financial-officer/2477662/BVI announced that it has named David Murray as Chief Financial Officer. Most recently, Mr. Murray served as Chief Financial Officer of Alcon from 2015 until its $30bn spin-off from Novartis Group AG in 20
- Oculis Elects Anthony Rosenberg and David A. Weber to Its Board of Directorshttps://modernod.com/news/oculis-elects-anthony-rosenberg-and-david-a-weber-to-its-board-of-directors/2479867/Oculis announced the appointments of Anthony Rosenberg as Non-Executive Chairman and David A. Weber, PhD, as Non-Executive Director. Together, they bring more than 60 years’ experience from the global pharmaceutical and eye care industries to the compa
- EyeCare Partners Promotes David Clark to Chief Executive Officerhttps://modernod.com/news/eyecare-partners-promotes-david-clark-to-chief-executive-officer/2479099/EyeCare Partners LLC announced the promotion of David A. Clark to chief executive officer, effective immediately. Mr. Clark joined EyeCare Partners as president in July 2020 after 20 years with MEDNAX Inc., where he was most recently ch
- EyePoint Pharmaceuticals Appoints David Price as Chief Financial Officerhttps://modernod.com/news/eyepoint-pharmaceuticals-appoints-david-price-as-chief-financial-officer/2479969/EyePoint Pharmaceuticals announced the appointment of David Price as Chief Financial Officer, effective immediately. In this role, Mr. Price will oversee and lead the company’s financial and capital markets activities. Mr. Price brings to EyePoint more than 25 years of financial experience